Qualcomm Tricoder Xprize wants to give everyone access to cutting edge diagnostics

Finalists of Tricorder XPrize announced

Ten teams developing a Star Trek inspired device for detection and diagnosis of dangerous diseases have made the finals of the Qualcomm-funded Tricorder XPrize.

Launched in January 2012, the competition encourages teams from around the world to develop a handheld, portable, consumer-focused diagnostic device that would be able to diagnose 15 medical conditions and capture five vital health metrics.

Teams from six countries representing academia, technology start-ups as well as non-profit organisations and established technology manufacturers have made the shortlist.  

“Our selected finalists represent the most promising and innovative submissions as determined by our expert judging panel,” said Grant Campany, senior director at Qualcomm Tricorder XPRIZE.

“We want consumers to take a more proactive approach to managing their health and having convenient access to real-time medical data will do just that. As we move to the final stage of this process, we are one step closer to putting healthcare in the palm of your hand.”

The competition participants had to deliver an assessment of safety, user experience and health as part of the qualifying round. A 21-strong judging panel of experts from the digital health and medical industry than selected the finalists who will now have about a year to develop the final design and prove its capabilities in a series of tests.

“The technologies being created for the Qualcomm Tricorder XPRIZE can have an exponential, global impact, not only on remotely diagnosing diseases, but on a myriad of other medical areas, including continuous health monitoring, disease prevention and chronic disease management,” said Rick Valencia, Senior Vice President & General Manager at Qualcomm Life.

“It will certainly be exciting to see these devices materialise as we move closer to the competition’s end.”

Throughout the competition, the US Food and Drug Administration (FDA) is offering regulatory input to the competing teams to help them prepare for potential FDA review post-competition.

The winners, receiving a $10m cash boost, will be announced in early 2016.

The shortlist was announced during the opening ceremony of the IEEE Engineering in Medicine and Biology Society International Conference,

The 10 teams advancing to the final round are:

Aezon (Rockville, Md.), led by Tatiana Rypinski, a team of student engineers from Johns Hopkins University partnering with the Center for Bioengineering Innovation & Design.

CloudDX (Mississauga, Canada), a team from medical devices manufacturer Biosign and led by company chief medical officer, Dr. Sonny Kohli.

Danvantri (Chennai, India), a team from technology manufacturer American Megatrends India and led by company Director and CEO, Sridharan Mani.
DMI (Cambridge, Mass.), a team led by Dr. Eugene Y. Chan of the DNA Medicine Institute partnering with NASA, the National Institutes of Health and the Bill and Melinda Gates Foundation.

Dynamical Biomarkers Group (Zhongli City, Taiwan), a team of physicians, scientists and engineers led by Harvard Medical School professor Chung-Kang Peng.

Final Frontier Medical Devices (Paoli, Pa.), a team led by the founders of Basil Leaf Technologies—brothers Dr. Basil Harris, an emergency room physician, and George Harris, a network engineer.

MESI Simplifying diagnostics (Ljubljana, Slovenia), a team from diagnostic medical device manufacturer MESI and led by company CEO, Jakob Susteric.

SCANADU (Moffett Field, Calif.), a team from Silicon Valley-based start-up, led by technology entrepreneur and company co-founder and CEO, Walter De Brouwer.

SCANurse (London, England), a team from diagnostic medical manufacturer led by biomedical engineer and company founder, Anil Vaidya.

zensor (Belfast, Ireland), a team from clinical sensor and electrode company Intelesens and led by chief technology officer, Proffesor Jim McLaughlin.

Recent articles

Info Message

Our sites use cookies to support some functionality, and to collect anonymous user data.

Learn more about IET cookies and how to control them